Taxonomy

CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

TAKE ACTION! Sign the Petition to Accelerate CMT-SORD

What is CMT-SORD? In 2019, with Charcot-Marie-Tooth Association (CMTA) funding,

CMTA Announces Addition of Health Insurance Industry Veteran Wendy Arnone to the Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT

Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication

Evolution: CMTA Board Welcomes Coulie & Marks

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research

The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing

The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher

It is with the heaviest of hearts that the Charcot-Marie-Tooth

CMT2S Breakthrough

In a recent announcement, Vanda Pharmaceuticals Inc. shared that the

CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD

In a statement released on February 15, 2024, by Charcot-Marie-Tooth